Molly Saunders

Molly Saunders became the Director of Regenerative Medicine Programs at Britecyte in January 2024. Previously, she held a key position as a Senior Manager on the Clinical Operations team at Osiris Therapeutics for several years. In this capacity, Molly managed numerous multi-center studies involving tissue-based products, overseeing aspects extending to vendor and contract organization management. Following the company’s acquisition by Smith+Nephew in 2019, she expanded her expertise to include the management of medical device studies. Throughout her tenure at Osiris, Molly played a pivotal role in co-authoring several publications describing the clinical and commercial applications of tissue-based products across various indications. These publications provided crucial evidence that was essential for obtaining market access and reimbursement. Before joining Britecyte, Molly further developed her professional experience as a consultant in the Life Sciences Group at Alvarez & Marsal. In this role, she specialized in rapid diligence assessments, cost-savings analyses, and profitability assessments, identifying millions in near-term EBITDA impact. The strategic counsel, in which Molly actively participated, played a crucial role in guiding private equity investments and contributing to the optimization and growth initiatives of life science organizations.

Molly earned a BS degree in Chemical and Biomolecular Engineering with a concentration in Bioengineering from the Johns Hopkins University. Additionally, she was previously recognized as a Certified Clinical Research Professional (CCRP) by the Society of Clinical Research Associates (SOCRA).